Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
British Journal of Diabetes · 2019
DOI: 10.15277//bjd.2019.208 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Diabetes, 2019. Verfasst von Umesh Dashora und 5 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
SGLT-2 inhibitors may be increasingly used in people with type 1 diabetes as new licenses are obtained. These drugs have the potential to improve glycaemic control in people with type 1 diabetes with the added benefit of weight loss, better control of blood pressure and more time in optimal glucose range. SGLT-2 inhibitors are associated with higher incidence of diabetic ketoacidosis without significant hyperglycaemia. The present ABCD position statement is to mitigate this risk and other potential complications in people taking these drugs. Particular caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diet, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin administration among other precipitating factors for diabetic ketoacidosis.
Zitieren
APA
Dashora, U., Patel, D. C., Gregory, R., Winocour, P., Dhatariya, K., & Nagi, D. (2019). Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019). British Journal of Diabetes. https://doi.org/10.15277//bjd.2019.208
Vancouver
Dashora U, Patel DC, Gregory R, Winocour P, Dhatariya K, Nagi D. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019). British Journal of Diabetes. 2019. doi:10.15277//bjd.2019.208
BibTeX
@article{Dashora2019,
author = {Dashora, Umesh and Patel, Dipesh C and Gregory, Robert and Winocour, Peter and Dhatariya, Ketan and Nagi, Dinesh},
title = {Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)},
journal = {British Journal of Diabetes},
year = {2019},
doi = {10.15277//bjd.2019.208}
}
EUVIMED